Join us in Dublin for the IASLC 2026 Hot Topic Meeting at Trinity College Dublin! This focused, two-day event will explore the evolving challenge of resistance to immunotherapy in lung cancer care in an interactive and collaborative setting.
What to expect:
• Expert-led presentations
• Panel discussions with practical insights
• Interactive sessions that encourage conversation and shared learning
🗓️ June 26–27
Registration and abstract submissions open in March.
Applications are still open for two incredible STARS opportunities!
💻 STARS Patient Research Advocate (PRA) Program
An all-virtual training program for patients and caregivers who want to engage meaningfully in lung cancer research.
🌍 STARS Scholar Program
An in-person opportunity at WCLC 2026 for experienced research advocates, including travel support and exclusive programming.
🗓 Application deadline: March 12, 2026
Whether you’re just beginning your advocacy journey or ready to take your impact to the global stage, STARS offers a pathway to grow, connect, and contribute.
📝 Applications Are Still Open – IASLC Reviewer Workshop at WCLC 2026!
IASLC, in collaboration with Journal of Thoracic Oncology (JTO) and JTO Clinical and Research Reports (JTO CRR), is still accepting applications for the one-day Reviewer Workshop at the IASLC 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea.
This interactive workshop is designed to strengthen manuscript review skills for early- and mid-career investigators through practical guidance from experienced editors and faculty.
📅 September 15, 2026
📍 Seoul, Republic of Korea
Director: Alex A. Adjei, MD, PhD, FACP
Who Should Apply?
✔ IASLC members within 15 years of completing specialist training
✔ Strong command of English
✔ Priority given to current JTO & JTO CRR reviewers
✔ Open to applicants from the Asia-Pacific region
✔ Non-members must apply for IASLC membership
Why Apply?
✨ Complimentary WCLC 2026 registration
✨ Travel & accommodation covered
✨ Expert training in academic publishing & peer review
📄 Application Requirements:
• CV (education & publications)
• Letter of Commitment (max 300 words)
• Letter of Support from supervisor, department head, or IASLC member
🎧 Lung Cancer Considered episode in Cantonese!
Guest host Dr. Molly Li brings together thoracic surgeons Dr. Shuben Li and Dr. Calvin S. H. Ng for a thoughtful conversation on surgical care for early-stage NSCLC.
They discuss:
• Surgical management strategies
• Lobar vs. sublobar resection
• Endobronchial therapy
• Tubeless anesthesia and other innovations
This episode is part of IASLC’s world languages series, expanding access to expert insights across the global community.
🎙️ New episode now streaming on Lung Cancer Considered!
Host Dr. Narjust Florez sits down with Dr. Sandip Patel to explore how artificial intelligence is shaping lung cancer care. From its impact on patient experience to how clinicians can better understand and use AI, this conversation takes a thoughtful look at where technology meets patient-centered care.
⏰ Last call! Regular registration for the Targeted Therapies of Lung Cancer Conference (TTLC) closes tomorrow.
Join leading experts for cutting-edge insights, real-world case discussions, and the latest advances shaping targeted therapies in lung cancer care. Don’t miss your chance to be part of the conversation.
If lung cancer is treatable when found early, why don’t we screen everyone?
Jan Pezarro, a patient advocate and survivor, explains why universal, age-based lung cancer screening could save lives and money in the long run.
Read Jan’s perspective in ILCN and join the conversation about prevention, access, and equity.
Advocate and survivor Jan Pezarro details how investing in a universal age-based lung cancer screening model can save both lives and health care costs.
02/07/2026
Tomasik and Dziadziuszko bring key insights to the forefront in their conclusion to this two-part series, highlighting unresolved questions and future directions for integrating HA-PCI and SRS into practice for small cell lung cancer (SCLC).
Read now:
In the conclusion of this two-part series, Drs. Tomasik and Dziadziuszko highlight unresolved questions and future directions for integrating HA-PCI and SRS into practice for SCLC.
02/06/2026
In a new ILCN article, Dr. Stephen Liu highlights the potential role for zenocutuzumab as a first-line therapeutic option for patients with NRG1-positive cancers.
Read now:
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.
02/04/2026
📣 Calling early- & mid-career investigators in the Asia-Pacific region!
IASLC, in collaboration with JTO, is hosting a Reviewer Workshop at 🌏✨
Selected participants will receive:
✔️ Complimentary WCLC registration
✔️ Travel & accommodation support
✔️ Additional exclusive benefits
How does war and displacement impact lung cancer care? Dr. Narjust Florez speaks with Dr. Julie Gralow and Dr. Rafal Dziadziuszko about disrupted care, growing inequities, and opportunities for collaboration in conflict settings.
Be the first to know and let us send you an email when International Association for the Study of Lung Cancer posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Contact The Practice
Send a message to International Association for the Study of Lung Cancer:
The International Association for the Study of Lung Cancer (IASLC) is on a mission to conquer thoracic cancers worldwide. Through hosting global conferences, funding cutting-edge research and educating the health care community and the general public on all aspects of thoracic cancers, the IASLC strives to alleviate the burden lung cancer places on patients, families and communities.
Each year, the IASLC hosts the World Conference on Lung Cancer (WCLC), the world’s largest meeting dedicated solely to thoracic cancers. The WCLC regularly attracts over 7,000 thoracic cancer specialists from over 100 countries and offers attendees the chance to collaborate and network while learning about the latest updates in the field.
The IASLC Foundation supports the education of research fellows - who are the next generation of lung cancer physicians and scientists - by funding research fellowships. Since its inception, the foundation has given nearly $3.5 million to lung cancer research, and that number is on the rise.
Additionally, the IASLC publishes the Journal of Thoracic Oncology (JTO), a primary source for educational information related to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Over its publication history, the JTO has established itself as an authoritative resource in the field, and the journal recently saw its impact factor increase from 6.595 in 2016 to 10.336 in 2017.
The IASLC is a global and multidisciplinary organization that desires to build a international and inclusive lung cancer community. Whether you are an oncologist or surgeon, advocate or patient, we welcome your expertise, experience and voice in the ongoing fight against lung cancer. Join us!
